Qiming Venture Partners' Mao Shuo Named to 2025 Mid-Year U40 Outstanding Young Investors List
The awards aim to recognize all young professionals with sharp instincts and strong expertise.
Recently, Qimingpian released its 2025 Mid-Year U40 Outstanding Young Investors list, honoring young professionals with sharp vision and strong expertise.
Shuo Mao, Executive Director at Qiming Venture Partners, was named to the list.
Shuo Mao, Executive Director at Qiming Venture Partners
Named to
2025 Mid-Year U40 Outstanding Young Investors List
In the first half of 2025, China's equity investment market showed signs of recovery, driven by technological innovation and capital market reforms, with market confidence gradually rebuilding from a period of dormancy. During this pivotal time, every investor has been actively adapting to new changes, exploring new development models, seeking stability through change and opportunity within change — collectively advancing the industry's steady progress.
Source | Qimingpian
Past Highlights
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.